63) nd assess interventions that target these factors. |
64) t the most highly regulated transcription factors. |
65) ticipant reasons for refusal and cultural factors. |
66) elated, and treatment-related confounding factors. |
67) entional, modifiable cerebrovascular risk factors. |
68) nterventions to improve MetS-related risk factors. |
69) cus with limited discussion of protective factors. |
70) rovider-, and healthcare system‑related factors. |
71) d by complex socio-cultural and religious factors. |
72) demiological studies of occupational risk factors. |
73) ressors in combination with personal risk factors. |
74) llenging process involving many competing factors. |
75) ful care indicate potential vulnerability factors. |
76) ferent from migrants' wives, net of other factors. |
77) ic, anthropometric, metabolic, and social factors. |
78) IV infection rates/testing and behavioral factors. |
79) ity in Brazil are likely related to these factors. |
80) n ambulatory patients due to a variety of factors. |
81) ons (43.9%) assessed multiple cancer risk factors. |
82) ich existing assessment tools capture DEI factors. |
83) he epidemiology of ALS and potential risk factors. |
84) ere all identified as potentially harmful factors. |
85) ible factor (HIF) family of transcription factors. |
86) d to be important mediating or moderating factors. |
87) romantic relationships due to unique risk factors. |
88) t and gene-gene interactions, among other factors. |
89) rkinson's disease (PD) risk and lifestyle factors. |
90) identified for several built environment factors. |
91) 19 vaccines and the potential influencing factors. |
92) ocial support were reported as protective factors. |
93) may be related to unknown cohort-specific factors. |
94) tumor dose, gross tumor volume and other factors. |
95) ith consideration of clinical significant factors. |
|